Cellect Biotechnology Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shai Yarkoni
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 23 Hata'as Street Kfar Saba Israel 44425
- IPO Date
- Jul 29, 2016
- CIK
- 0001671502
- Website
- cellect.co
- Similar Companies
- Business
- Cellect Biotechnology Ltd. (APOP) develops innovative cell selection technologies for stem cell-based therapies and regenerative medicine. The company offers ApoGraft, a proprietary platform that employs FasL-induced apoptosis to functionally select and enrich stem cells while depleting mature cells, thereby enhancing the safety and efficacy of hematopoietic stem cell transplantation, bone marrow transplants for hematological malignancies, and other regenerative applications; ApoTainer, a kit supporting ex vivo stem cell processing for transplant procedures; and related tools enabling scalable production of clinical-grade FasL for research, clinical trials, and commercial cell therapy manufacturing. Founded in 2011 and headquartered in Kfar Saba, Israel, Cellect Biotechnology primarily serves pharmaceutical companies, research institutes, hospitals, and biobanking facilities focused on adult stem cell therapies, with operations centered in Israel and collaborations extending internationally. In October 2021, Cellect Biotechnology was acquired by Quoin Pharmaceuticals, Inc. through a reverse merger transaction, after which the combined entity adopted the name Quoin Pharmaceuticals Ltd. while retaining the APOP ticker; the company has pursued partnerships including with XNK Therapeutics for NK cell-based therapeutics, denovoMATRIX for regenerative product synergies, and Cell2in Inc. for stem cell quality assessment via FreSHtracer technology; it completed scale-up of clinical-grade FasL manufacturing in 2019 to support global clinical activities and expanded its pipeline through ongoing bone marrow transplantation trials.
Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals
5 Short Squeeze Candidates To Watch: Aterian, Marin On List Again, Plus 3 New Small-Cap Medical Plays
Here's why Cellect Biotechnology shares are up 50% on Monday
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals
APOP Stock: Over 70% Increase Pre-Market Explanation
See Why Cellect Biotechnology Stock Is Soaring During Premarket Friday
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.
Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results
Cellect Biotechnology Shares Increase Over 10% Pre-Market: Why It Happened
The Securities and Exchange Commission Declared Cellect Biotechnology's Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals
Best Biotech Penny Stocks to Buy in July 2021? 6 For Your Watchlist
Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop
These Penny Stocks Are Up Big Today, Worth It or Not?
Why Are Cellect Biotechnology (APOP) Shares Surging Today?
APOP Stock Price Increases Over 55% Pre-Market: Why It Happened
Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals
Are These Penny Stocks The Biggest Morning Movers?
5 Hot Penny Stocks To Buy? Check These Out For May 2021
Market Update: The 10 Most Volatile Stocks Today